Myristoyl Pentapeptide-4 (Myr-KTTKS) (CAS 1392416-25-9) is supplied by TCS NEXUS S.L. (Valencia, Spain) for European cosmetic formulators, brand R&D teams and B2B buyers reviewing cosmetic peptide raw material applications. With limited direct water solubility, it requires propylene glycol or ethanol pre-dispersion before aqueous dilution, at pH 4.5–7.0, with incorporation below 40°C in standard emulsion manufacturing protocols.
> Technical Specifications
| Product Name | Myristoyl Pentapeptide-4 (Myr-KTTKS) |
|---|---|
| Molecular Structure |  |
| CAS Number | 1392416-25-9 |
| Alias / Common Name | Myristoyl Pentapeptide-4; Myr-KTTKS; myristoyl-Lys-Thr-Thr-Lys-Ser |
| Molecular Formula | C37H71N7O10 |
| Molecular Weight | 774.0 g/mol |
| INCI Name | Myristoyl Pentapeptide-4 |
| Peptide Sequence | Myristoyl-Lys-Thr-Thr-Lys-Ser — Myr-KTTKS (KTTKS matrix signal peptide with C14 myristoyl anchor) |
| Functional Class | Synthetic lipopeptide; fibronectin-signalling matrix active; collagen I and III synthesis modulator; C14 myristoyl carrier peptide; Matrixyl class matrix signal lipopeptide |
| Purity / Assay | ≥98% (HPLC); confirm by batch COA |
| Appearance | White to off-white powder |
| Solubility / Handling | Lipopeptide; limited direct water dispersibility. Pre-disperse in propylene glycol (5–15%) at 40–50°C before adding to the formulation at cool-down below 40°C. |
| pH Stability | Optimal stability at pH 4.5–7.0. Confirm stability in the complete formulation base. |
| Storage | Store sealed below 25°C in a cool, dry location protected from direct light and moisture. Follow SDS and batch COA conditions. |
> Mechanism & Positioning
Myristoyl Pentapeptide-4 (Myr-KTTKS) is a C14 myristoyl lipopeptide analogue of the KTTKS fibronectin-derived matrix signal sequence — a pentapeptide derived from the collagen I pro-alpha chain that binds fibronectin and fibronectin receptor complexes in the dermal ECM. Published Myristoyl Pentapeptide-4 literature discusses agonism at the fibronectin receptor (integrin α5β1/FNIII repeats), triggering a TGF-β-like downstream signalling cascade in dermal fibroblasts. Cell-based fibroblast studies document upregulation of collagen I, collagen III and fibronectin gene expression, with observed increases in procollagen I C-peptide (PICP) secretion in culture supernatant assays. ECM remodelling model data also notes MMP-1 and TIMP-1 ratio improvements consistent with net matrix-building rather than net matrix-degrading activity. The C14 myristoyl anchor provides lipid-phase solubility and membrane affinity analogous to the C16 palmitoyl anchor in Palmitoyl Pentapeptide-4 (Matrixyl), making Myr-KTTKS a myristoyl-series Matrixyl-class matrix signal lipopeptide.
Myristoyl Pentapeptide-4 builds multi-lipopeptide ECM systems with Palmitoyl Tripeptide-1 (Pal-GHK) for TGF-β/fibronectin co-signalling and Palmitoyl Tetrapeptide-7 (Rigin) for cytokine-driven matrix degradation control. For DEJ and elastin breadth, add Palmitoyl Hexapeptide-12 (Biopeptide-EL) and Palmitoyl Tetrapeptide-10. Contact info@tcspeptides.com with formulation specification.
> Application Concepts
Matrixyl-Class ECM Serum and Myristoyl Lipopeptide Architecture
Myristoyl Pentapeptide-4 at 0.001–0.1% requires PG pre-dispersion (5–15 parts PG per 1 part peptide, 40–50°C, gentle stirring) before addition to the formulation at cool-down below 40°C. It integrates into emulsions, serum-in-emulsion formats and PG-based aqueous serums at pH 5.0–6.5. For a clean dual-KTTKS-class serum, combine Myristoyl Pentapeptide-4 with palmitoyl pentapeptide-equivalent actives in a shared PG pre-dispersion at combined lipopeptide concentrations up to 0.2% total. At comparable fibronectin receptor targeting concentrations, the C14 myristoyl anchor may offer different skin-surface kinetics from the C16 palmitoyl anchor — evaluate both in stability and efficacy screening.
Myristoyl vs Palmitoyl Lipopeptide Anchors — Kinetic and Delivery Differences in KTTKS Matrix Signal Peptides
The KTTKS matrix signal peptide sequence (Lys-Thr-Thr-Lys-Ser) has been characterised with both C14 myristoyl (Myristoyl Pentapeptide-4) and C16 palmitoyl anchors (Palmitoyl Pentapeptide-4 / Matrixyl). The shorter C14 chain in Myristoyl Pentapeptide-4 may result in different lipid bilayer insertion depth and membrane dissociation kinetics compared to C16 palmitoyl anchors, potentially affecting delivery rate across the SC lipid lamellae. Both lipopeptides share the same KTTKS receptor-targeting sequence but differ in lipid anchor length and overall lipophilicity — providing a means to compare SC delivery profiles while maintaining the same fibronectin receptor interaction. Evaluate Myristoyl Pentapeptide-4 alongside Palmitoyl Tripeptide-1 in the same stability and efficacy screen to establish the contribution of anchor chain length to formulation performance.
Premium Anti-Age Emulsion and Concentrate Format Applications
Myristoyl Pentapeptide-4 integrates into premium anti-age day creams, night concentrates and targeted treatment serums formulated at 0.001–0.1%. For a comprehensive four-lipopeptide anti-age night concentrate targeting collagen I/III (Myr-KTTKS and Pal-GHK), elastin (Pal-VGVAPG), DEJ fibronectin (Pal-KTFK) and inflammatory MMP suppression (Rigin), prepare a combined PG pre-dispersion of all four lipopeptides at the individual target concentrations, then add to the emulsion base at cool-down. Confirm total PG contribution (all four pre-dispersions combined) is within the final formulation tolerance — typically ≤5% total PG in a finished serum. Evaluate the combined lipopeptide system stability at 40°C/75% RH before scale-up.
> Handling & Formulation Notes
Pre-disperse Myristoyl Pentapeptide-4 in propylene glycol (5–15 parts PG per 1 part peptide) at 40–50°C with gentle stirring until uniform dispersion is achieved. Add the PG dispersion to the formulation at cool-down below 40°C. Avoid direct addition of undispersed powder to hot aqueous phases. Avoid prolonged heating above 45°C to protect the myristoyl amide bond.
Confirm stability of Myristoyl Pentapeptide-4 in the complete formulation at 40°C/75% RH for 12 weeks before scale-up. Monitor lipopeptide integrity by HPLC when formulating at pH outside 4.5–7.0. Follow SDS and batch COA for storage and handling; confirm shelf life for the specific batch. EDTA at ≤0.1% is compatible as a chelating buffer in emulsion systems; avoid strong oxidising agents (H₂O₂ ≥1%, benzoyl peroxide) and high-pH bases above pH 8.0.
> Supply & Documentation
Myristoyl Pentapeptide-4 (Myr-KTTKS) (CAS 1392416-25-9) is available from TCS NEXUS S.L. (Valencia, Spain) for B2B cosmetic raw material projects. Standard documentation: COA, TDS, SDS. Sample and bulk quantities are discussed on a per-project basis; contact info@tcspeptides.com to initiate a sourcing review.
TCS NEXUS S.L. supports procurement and formulation teams in Germany, France, Italy, Spain, the United Kingdom, the Netherlands, Belgium, Poland, Sweden and Portugal, as well as international buyers in the United States, Canada, Japan, South Korea, Australia and New Zealand.
> Packaging & Storage
Myristoyl Pentapeptide-4 (Myr-KTTKS) is supplied in sealed aluminium foil bags or bulk containers. Minimum quantities and packaging configurations are confirmed per order. Store below 25°C in a cool, dry location, away from moisture and direct light. Follow batch COA and SDS for specific storage and handling conditions.
> FAQ
What is Myristoyl Pentapeptide-4 (Myr-KTTKS)?
Myristoyl Pentapeptide-4 (Myr-KTTKS) (CAS 1392416-25-9) is a cosmetic raw material supplied by TCS NEXUS S.L. (Valencia, Spain) for B2B cosmetic formulators. In cosmetic literature, Myristoyl Pentapeptide-4 is the myristoylated analogue of the Matrixyl (Pal-KTTKS) pro-collagen pentapeptide — evaluated in anti-ageing serums and emulsions where the C14 myristoyl chain offers an alternative lipid-penetration profile to the C16 palmitoyl chain. TCS NEXUS S.L. supplies Myristoyl Pentapeptide-4 as a B2B active for formulators exploring lipopeptide variants in anti-ageing and skin-density formulations.
What is the CAS number for Myristoyl Pentapeptide-4 (Myr-KTTKS)?
The CAS number for Myristoyl Pentapeptide-4 (Myr-KTTKS) is 1392416-25-9. The INCI name for cosmetic regulatory documentation and CPNP notification is Myristoyl Pentapeptide-4; confirm CAS 1392416-25-9 and INCI identity against the batch COA when building product files.
How does Myr-KTTKS signal collagen synthesis — what is the matrikine mechanism?
Myristoyl Pentapeptide-4 (Myr-KTTKS) carries the KTTKS pentapeptide (Lys-Thr-Thr-Lys-Ser), a subfragment of type I procollagen, joined to a C14 myristoyl lipid anchor. As a matrikine it signals through the fibronectin pathway to prompt fibroblasts to upregulate type I and III collagen, fibronectin and glycosaminoglycan synthesis for extracellular-matrix renewal. The myristoyl chain provides lipophilicity so the KTTKS signal can cross the stratum corneum.
What use level of Myr-KTTKS is typical, and does the pure vs trade-solution basis matter?
Rather than quoting one fixed figure, evaluate the use level conservatively — it varies with the formulation system, the claim and your own testing. KTTKS lipopeptides are often supplied as diluted trade solutions, whereas we provide the pure peptide with COA for precise pure-peptide dosing. Contact info@tcspeptides.com to align documentation with your dosing basis.
Which actives pair with Myr-KTTKS in an age-care system?
Myr-KTTKS layers with other matrix-signal peptides such as Palmitoyl Tripeptide-1 (Pal-GHK) and Palmitoyl Tetrapeptide-7 (Rigin), with copper-delivery GHK-Cu for lysyl-oxidase crosslinking, and with niacinamide for tone and barrier. As a lipopeptide it needs pre-dispersion before combining; confirm clarity and pH in the finished emulsion base.
How does Myr-KTTKS differ from Matrixyl (Palmitoyl Pentapeptide-4)?
Both deliver the same KTTKS matrix-signalling pentapeptide, but through different lipid anchors: Myristoyl Pentapeptide-4 uses a C14 myristoyl chain, while Matrixyl (Palmitoyl Pentapeptide-4, Pal-KTTKS) uses a C16 palmitoyl chain. The shorter myristoyl anchor changes the lipophilicity and dispersion behaviour while keeping the same procollagen-derived signal; the choice is usually driven by formulation feel, solubility handling and supplier preference. Both are lipopeptides that require pre-dispersion.
How should the lipopeptide Myr-KTTKS be pre-dispersed and added?
Because it is a lipopeptide with limited water dispersibility, pre-disperse Myristoyl Pentapeptide-4 in about 5–15% propylene glycol warmed to 40–50°C before adding it to the formulation. Introduce it at cool-down below 40°C, then confirm solution clarity and finished pH; standard emulsion cool-down protocols are compatible.
What pH range keeps Myr-KTTKS stable in a finished emulsion?
Myristoyl Pentapeptide-4 is most stable at pH 4.5–7.0, matching common serum and emulsion targets. Confirm the finished-product pH after all actives and buffering agents are incorporated, and evaluate combined stability where it shares a base with low-pH actives such as ascorbic acid.
Is Myristoyl Pentapeptide-4 (Myr-KTTKS) compatible with other actives in multi-active cosmetic systems?
Myristoyl Pentapeptide-4 (Myr-KTTKS) is compatible with standard cosmetic actives at pH 4.5–7.0 in aqueous or emulsion systems. Evaluate combined system pH drift, clarity and assay retention; confirm preservative compatibility. Run accelerated stability testing at 40°C/75% RH before scale-up.
Is Myristoyl Pentapeptide-4 (INCI) compliant with EU Cosmetics Regulation 1223/2009?
Myristoyl Pentapeptide-4 is not listed as a restricted, prohibited or regulated substance under EU Cosmetics Regulation 1223/2009 Annexes II–VI. The finished product manufacturer is responsible for the CPSR and CPNP notification. Use CAS 1392416-25-9 and INCI name Myristoyl Pentapeptide-4 consistently in all regulatory documentation; confirm purity and identity against the batch COA.
How should Myristoyl Pentapeptide-4 (Myr-KTTKS) be stored?
Store Myristoyl Pentapeptide-4 (Myr-KTTKS) sealed below 25°C in a cool, dry location protected from direct light and moisture. Once opened, reseal the container immediately. Follow specific storage and handling conditions stated in the SDS and batch COA. Confirm shelf life for the specific batch before incorporating into production formulations.
What documentation does TCS NEXUS S.L. provide for Myristoyl Pentapeptide-4 (Myr-KTTKS)?
TCS NEXUS S.L. provides COA (confirming CAS 1392416-25-9 and HPLC purity ≥98% (HPLC)), TDS (Technical Data Sheet) and SDS (Safety Data Sheet) for Myristoyl Pentapeptide-4 (Myr-KTTKS). Additional documentation such as specification sheets and INCI confirmation letters is available on a per-project basis. Contact info@tcspeptides.com to initiate a documentation and sourcing discussion.
What MOQ and sample options are available for Myristoyl Pentapeptide-4 (Myr-KTTKS)?
Sample and bulk quantities for Myristoyl Pentapeptide-4 (Myr-KTTKS) are confirmed on a per-project basis through TCS NEXUS S.L. Minimum order quantities depend on current stock, packaging configuration and project scope. R&D teams are encouraged to request samples for stability and concentration-range evaluation before bulk planning. Contact info@tcspeptides.com with project specification to begin a sourcing review.
> Technical Support and Samples
Request COA documents, sample availability, or support for custom synthesis.